BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.97
-0.72 (-0.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close87.69
Open86.99
Bid0.00 x 1200
Ask0.00 x 800
Day's Range86.42 - 87.59
52 Week Range79.13 - 106.74
Volume911,120
Avg. Volume1,147,019
Market Cap15.574B
Beta (3Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com2 days ago

    BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says

    J.P. Morgan analyst Cory Kasimov said Wednesday that BioMarin is undervalued. He said the firm is in strong shape, even if its gene-therapy results are disappointing.

  • BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher
    Zacks8 days ago

    BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher

    BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • TheStreet.com10 days ago

    2 Stocks You Definitely Should Consider Shorting This Week

    Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.

  • Read This Before Buying BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares
    Simply Wall St.14 days ago

    Read This Before Buying BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • BioMarin Bulls Are Counting on Gene Therapy to Reignite the Stock
    Bloomberg15 days ago

    BioMarin Bulls Are Counting on Gene Therapy to Reignite the Stock

    BioMarin Pharmaceutical Inc. is set to announce results of its medicine, Valrox, that will show how durable the next-generation drug is three years after dosing. The update has been seen across Wall Street as the next key value driver for shares and could spur the stock to either rise or fall as much as 25 percent, according to Wedbush. Investors have become increasingly wary of how much the medicine’s benefit will decline compared to two-year results.

  • Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
    Zacks15 days ago

    Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

    Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

  • TheStreet.com16 days ago

    Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs

    The markets have been rocked this week by escalating trade tensions between the U.S. and China as well as potentially new tariffs on the horizon. As such, valrox, if efficacy is durable, has the potential to be the largest product for BioMarin.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.
    American City Business Journals17 days ago

    Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.

    Netflix and Google employees are now in Silicon Valley's $200K club. The typical Googler earned $246,804 last year — up 25 percent year-over-year. At Netflix, the median employee made $202,335 last year after getting a 10 percent pay boost over 2017.

  • Benzinga22 days ago

    5 Biotech Stocks With Near-Term Catalysts Ahead

    The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.

  • BioMarin Isn't a "Gene Therapy Company"
    Motley Fool23 days ago

    BioMarin Isn't a "Gene Therapy Company"

    Despite the biotech's move into gene therapy, its bread and butter are still paying the bills.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of BMRN earnings conference call or presentation 25-Apr-19 8:30pm GMT

    Q1 2019 Biomarin Pharmaceutical Inc Earnings Call

  • BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat
    Zacks28 days ago

    BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

    BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

  • Benzinga28 days ago

    The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...

  • Biomarin Pharmaceutical Inc (BMRN) Q1 2019 Earnings Call Transcript
    Motley Fool28 days ago

    Biomarin Pharmaceutical Inc (BMRN) Q1 2019 Earnings Call Transcript

    BMRN earnings call for the period ending March 31, 2019.

  • Associated Press28 days ago

    BioMarin: 1Q Earnings Snapshot

    The San Rafael, California-based company said it had a loss of 32 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, came to 14 cents per share. The results beat Wall ...

  • Benzinga29 days ago

    The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...

  • Zackslast month

    Solid Earnings Boost S&P, NASDAQ to New Closing Highs

    Solid Earnings Boost S&P;, NASDAQ to New Closing Highs

  • MoneyShowlast month

    Long-Term "GameChangers" in Biotech

    When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO ) filing for Chapter 11 bankruptcy and negative clinical readouts ...

  • Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline
    Zackslast month

    Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline

    BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CNBClast month

    As Nasdaq 100 hits record, Apple and Intel could still be buys, says expert

    The Nasdaq 100 just hit a record, but that doesn't mean buying tech is off the table, one expert says. The tech-heavy index made an all-time high Wednesday morning, helped by a 4% surge in shares of Intel INTC . "I think Intel had the most constructive pullback to those December lows, which was a double bottom," Baruch said Tuesday on CNBC's "Trading Nation," pointing to the semiconductor company's three-year chart.

  • New Strong Sell Stocks for April 16th
    Zackslast month

    New Strong Sell Stocks for April 16th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • 8 Stocks May Jump on Takeovers as Market Nears Peak
    Investopedialast month

    8 Stocks May Jump on Takeovers as Market Nears Peak

    Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.